A synthetic leukotriene B₄ receptor type 2 agonist accelerates the cutaneous wound healing process in diabetic rats by indirect stimulation of fibroblasts and direct stimulation of keratinocytes

详细信息    查看全文

• 作者：Lin Luo^a ; ^b ; ^{donieluo@hotmail.com} ; Rica Tanaka^b ; ^{rtanaka@juntendo.ac.jp} ; Shigeyuki Kanazawa^b ; ^{sonic0311shige@yahoo.co.jp} ; Feng Lu^a ; ^{doctorlufeng@hotmail.com} ; Ayato Hayashi^b ; ^{ayhayasi@juntendo.ac.jp} ; Takehiko Yokomizo^c ; ^{yokomizo-tky@umin.ac.jp} ; Hiroshi Mizuno^b ; ^{hmizuno@juntendo.ac.jp}
• 关键词：Diabetes ; Wound healing ; Leukotriene B4 receptor type 2 ; Cay ; Keratinocyte ; Fibroblast
• 刊名：Journal of Diabetes and its Complications
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：31
• 期：1
• 页码：13-20
• 全文大小：799 K
• 卷排序：31

文摘

The synthetic leukotriene B4 receptor type 2 (BLT2) agonist CAY10583 (CAY) accelerates wound healing in diabetic mice by promoting keratinocyte migration. However, its effects on fibroblast activity and granulation are unknown. We investigated the mechanisms by which CAY promotes wound healing.MethodsCAY was applied to wounds on streptozotocin-induced diabetic rats, and wound closure, granulation thickness, and epithelialization gaps were analyzed. BLT2 expression was examined by RT-PCR. Migration and proliferation were studied by scratch assays and MTS assays. Keratinocyte supernatants with CAY were applied to fibroblasts, and cytokines were measured by enzyme-linked immunosorbent assays.ResultsCAY significantly accelerated wound healing in diabetic rats (CAY, 78.05 ± 12.22% vs. control, 59.84 ± 11.09%; p = 0.0222), with increased re-epithelialization and granulation compared to controls. BLT2 was expressed in keratinocytes, but not in fibroblasts. Keratinocyte treatment with the CAY supernatant enhanced fibroblast proliferation and migration (fibroblast scratch closure: CAY, 75.95 ± 4.09% vs. control, 49.69 ± 4.49%; p < 0.0001). CAY-treated keratinocytes exhibited increased TGF-β1 and bFGF expression.ConclusionsCAY directly promotes keratinocyte migration and indirectly enhances fibroblast proliferation by increasing keratinocyte production of TGF-β1 and bFGF, accelerating wound closure. CAY is a promising pharmaceutical agent for diabetic wounds.